Clinical trial
Prevention of Seasonal Affective Disorder
NCT00046241 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00046241 |
|---|---|
| Title | Prevention of Seasonal Affective Disorder |
| Official title | A 7 Month, Multicenter, Randomized, Double-blind, Placebo-controlled Comparison of 150-300mg/Day of Extended-release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Affective Disorder in Subjects With a History of Seasonal Affective Disorder Followed by an 8-week Observational… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Seasonal Affective Disorder |
| Intervention type | Drug |
| Interventions | Extended-release bupropion hydrochloride |
| Enrollment | 300 |
| Start date | Sep 1, 2002 |
| Primary completion | Jun 1, 2003 |
| Completion | Jun 1, 2003 |
| First posted | Sep 25, 2002 |
| Last update posted | Jan 23, 2017 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: